Avoro Capital Advisors’s Kymera Therapeutics KYMR Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$623M	Hold	7,474,747	–	–	6.13%	7
2025 Q4	$582M	Buy	7,474,747 +1,124,747	+18%	+$76M	5.72%	7
2025 Q3	$359M	Sell	6,350,000 -205,555	-3%	-$9.27M	4.65%	7
2025 Q2	$286M	Buy	6,555,555 +95,555	+1%	+$3.29M	5.01%	6
2025 Q1	$177M	Buy	6,460,000 +1,310,000	+25%	+$47.8M	2.76%	11
2024 Q4	$207M	Buy	5,150,000 +650,000	+14%	+$29.4M	2.93%	14
2024 Q3	$213M	Buy	4,500,000 +611,112	+16%	+$27M	3.11%	12
2024 Q2	$116M	Hold	3,888,888	–	–	1.55%	18
2024 Q1	$156M	Buy	3,888,888 +113,888	+3%	+$4.07M	1.82%	19
2023 Q4	$96.1M	Sell	3,775,000 -80,000	-2%	-$1.43M	1.33%	18
2023 Q3	$53.6M	Hold	3,855,000	–	–	0.84%	19
2023 Q2	$88.6M	Hold	3,855,000	–	–	1.2%	18
2023 Q1	$114M	Buy	3,855,000 +5,000	+0.1%	+$161K	1.69%	16
2022 Q4	$96.1M	Buy	3,850,000 +1,680,770	+77%	+$44.8M	1.44%	17
2022 Q3	$47.2M	Buy	2,169,230 +909,230	+72%	+$24M	0.87%	21
2022 Q2	$24.8M	Buy	1,260,000 +443,500	+54%	+$10.4M	0.49%	28
2022 Q1	$34.6M	Buy	816,500 +266,500	+48%	+$11.3M	0.63%	24
2021 Q4	$34.9M	Buy	550,000 +94,250	+21%	+$5.49M	0.59%	27
2021 Q3	$26.8M	Buy	+455,750	New	+$26.4M	0.42%	33
2020 Q4	–	Sell	-49,400	Closed	-$1.6M	–	47
2020 Q3	$1.6M	Buy	+49,400	New	+$1.51M	0.02%	46